Ezetimibe's Effect on Heart Attack Risk in Patients with High Cholesterol
Author Information
Author(s): John S. Sampalis, Stéphane Bissonnette, Stella Boukas
Primary Institution: McGill University
Hypothesis
Does coadministration of ezetimibe with statins reduce the estimated risk for cardiovascular mortality in patients with high cholesterol?
Conclusion
Ezetimibe combined with statins significantly reduces the estimated risk for cardiovascular mortality.
Supporting Evidence
- Patients treated with ezetimibe showed a significant decrease in LDL-C levels.
- The mean estimated Total CVD Mortality Risk decreased from 0.068 to 0.053.
- Co-administration of ezetimibe resulted in a 25% reduction in estimated CHD mortality risk.
- Statistically significant changes were observed in both CHD and total CVD mortality risks.
Takeaway
This study shows that taking ezetimibe with statins can help lower the chances of dying from heart problems for people with high cholesterol.
Methodology
A prospective cohort study measuring cardiovascular risk using the SCORE model before and after six weeks of treatment with ezetimibe and statins.
Potential Biases
Potential bias due to the observational nature of the study and reliance on the SCORE model developed in Europe.
Limitations
The study design was observational and used a single cohort, which may limit generalizability.
Participant Demographics
Mean age was 62 years, with 62.3% males; included patients with hypertension, diabetes, metabolic syndrome, and smokers.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.689–0.867
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website